中华临床医师杂志(电子版)最新文献

{"title":"Mechanism of Beclin1 as a favorable molecules marker is that Beclin1 inhibits tumor proliferation and cell cycle arrest in stage IIIB colon cancers","authors":"Li Bao-xiu, Zhang Xiao-shi","doi":"10.3877/29","DOIUrl":"https://doi.org/10.3877/29","url":null,"abstract":"Objective　Beclin1 is a multi-function protein，bridging autophagy，apoptosis and differentiation. Our previous study found that Beclin1 was a favorable prognostic biomarker in locally advanced colon carcinomas. This study investigated the expression of Beclin1 in human colon cancers and its mechanism as a favorable molecules marker. Methods　A total of 104 cases of colon cancer specimens and clinical data were obtained from Chinese stage ⅢB colon cancer patients with intact follow-up data who subjected to radical resection between Jan，1999 and July，2003 in the cancer center of Sun Yat-Sen University. The specimens were constructed from formalin-fixed，paraffin-embedded tissues. The expression of Beclin1 in primary tumors matched with adjacent noncancerous tissue were examined with immunohistochemistry technique. Additionally，immunofluorescence double staining technique was used to investigate the molecular mechanism by analyzing coexpression of the protein PCNA and Beclin1. Results　The expression of Beclin1 was observed in plasma-membrane，cytoplasm and nucleus in tumor cells. In the tumor tissues analyzed，immunopositivity was observed for Beclin1 in 87(83.7% ) of the 104 tumor tissues. In contrast，adjacent non-cancerous tissues and normal tissues showed no or very weak expression of Beclin1. The 5-year overall survival rate for Beclin1 immunopositivity cases was 69.8%. Beclin1 immunonegativity was 47.1%. Both univariate analysis and multivariate analysis showed that Beclin1 and T stage were independent prognostic factors. The immunofluorescence double staining showed the expression of Beclin1 negatively correlated with the expression of PCNA，which indicates Beclin inhibits tumor proliferation and cell cycle arrest. Conclusions　Beclin1 plays important roles in the regulation of the life span of human colon cells by inhibiting tumor proliferation and cell cycle arrest in stage ⅢB colon cancers. Beclin1 is a favorable prognostic biomarker in locally advanced colon carcinomas and provides the information regarding the likely targeted therapy intervention. In future，with the progress of autophagy analysis technique，it is critical to determine the autophagy pathway responsible for colon cancer in cell lines and animal models to define targets to fight the locally advanced colon cancer.","PeriodicalId":63159,"journal":{"name":"中华临床医师杂志(电子版)","volume":"4 1","pages":"395-401"},"PeriodicalIF":0.0,"publicationDate":"2010-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70278547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot study of mycobacteria infection in incomplete transverse myelitis refractory to steroids","authors":"Feng Yan-qing, G. Ning, H. Fan, Chen Xi, Sun Qiao-song, Liu Jun-xiu","doi":"10.3877/47","DOIUrl":"https://doi.org/10.3877/47","url":null,"abstract":"Objective　Incomplete transverse myelitis (ITM) of unknown origin is associated with high rates of morbidity and mortality，and treatment options for these patients are few. This pilot study was undertaken to determine whether antituberculous treatment(ATT)might help in patients with ITM whose condition continued to worsen despite receiving IV methylprednisolone treatment. Methods　This is a prospective，open-label study. A group of 67 patients with steroid-refractory ITM were included from Jan 2003 to Jun 2009，and known causes of myelopathy were excluded.They underwent trial chemotherapy of ATT. All patients were followed up for at least 1 year after treatment.Efficacy was assessed by the ASIA scoring system，Barthel Index(BI)and Hauser Ambulation Index(AI)at baseline and at 12 months，and magnetic resonance imaging(MRI)changes were also assessed. Results　Of 67 patients enrolled，16 withdrew. 51 patients completed the entire course of treatment;and were able to be assessed. At 12 months，49 patients experienced benefits. ASIA rating，BI significantly increased，Hauser AI improved validity，concomitantly with markedly decreased abnormal signals in spinal cord on MRI over time. Conclusions　The results from this perspective study provide beneficial clinical and MRI data on the efficacy of ATT in ITM patients，and suggests mycobacteria may be an important and being neglected infection of myelitis.","PeriodicalId":63159,"journal":{"name":"中华临床医师杂志(电子版)","volume":"4 1","pages":"23-28"},"PeriodicalIF":0.0,"publicationDate":"2010-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70278855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}